Document is current
Any future updates will be listed below
-
Authors
Tembo, Tannia
Heilmann, Elizabeth
Kabamba, Bupe Mulenga
Fwoloshi, Sombo
Kalenga, Kalubi
Chilambe, Felix
Siwinga, Mpanji
Rutagwera, Marie-Reine
Musunse, Maximillian
Kangale, Chabu
Yingst, Samuel
Yadav, Ruchi
Savory, Theodora
Gutman, Julie R.
Sikazwe, Izukanji
Mulenga, Lloyd B.
Moore, Carolyn Bolton
Hines, Jonas Z.
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention (NU2GGH002251-01-00)
Centers for Disease Control and Prevention (NU2GGH002251-01-00)
Centers for Disease Control and Prevention (NU2GGH002251-01-00)
Centers for Disease Control and Prevention (NU2GGH002251-01-00)
Centers for Disease Control and Prevention (NU2GGH002251-01-00)
- License Information
-
More Information
Article History
Received: 27 February 2024
Accepted: 12 February 2025
First Online: 28 February 2025
Declarations
:
: CIDRZ obtained ethics approval directly from the NHRA as there was a concession and expedited review of COVID-19-related studies. PATH obtained approval for the SARS-CoV-2 amendment to its original malaria surveillance protocol from NHRA and UNZABREC. This study was reviewed by CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.
: Not applicable (no individual details, images, or videos).
: The authors declare no competing interests.
